Oncobiologics Культура компании

Dr. Pankaj Mohan, Ph.D. founded Oncobiologics, Inc. in January 2011 and has been its Chairman, Chief Executive Officer and President since inception. From May 2008 to December 2010, Dr. Mohan served as head of Business Operations and Portfolio Management of Biologics Process and Product Development at Bristol-Myers Squibb Company. From June 2006 to May 2008, Dr. Mohan served as a Director of Bioprocess Engineering at Genentech, Inc., a biotechnology company. Prior to that Dr. Mohan served as a senior manager at Eli Lilly and Company. From May 1993 to April 1996, Dr. Mohan served as Assistant Professor (Lecturer/Fellow) at the Advanced Centre for Biochemical Engineering, University College London, London, United Kingdom. From August 1987 to December 1989, Dr. Mohan served as a Scientific Officer for the Department of Atomic Energy for the Government of India. Dr. Mohan has served as Chairman and as a member of the board of directors of Sonnet Biotherapeutics, Inc. since its inception in April 2015. Dr. Mohan received a Ph.D. in Biochemical Engineering from the School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom, a masters in Financial Management from Middlesex University Business School, London, United Kingdom, an Executive Management Program (AMP) from Fuqua School of Business at Duke University and a Bachelor of Chemical Engineering from the Indian Institute of Technology in Roorkee, India.

Dr. Stephen J. McAndrew, Ph.D. has been a Senior Vice President of Business Strategy & Development at Oncobiologics, Inc. since March 2014. Dr. McAndrew served as Vice President of Business Development at Oncobiologics, Inc. from May 2012 to March 2014. Dr. McAndrew was responsible for the Oncobiologics revenue growth strategy and initiatives, establishing and managing all collaborative research and commercial product partnerships and sourcing selected investment opportunities. Dr. McAndrew served as Vice President of Business Development for Xenogen Biosciences, Caliper Life Sciences and Taconic Biosciences. Dr. McAndrew served as Vice President of Pharmaceutical Business Development of Lexicon Genetics Inc. (AKA Lexicon Pharmaceuticals, Inc.) since January 2002. From March 1990 to December 2001, Dr. McAndrew served increasing levels of responsibility at Bristol-Myers Squibb Company, leading to his final position of Director of Biotechnology Licensing at the Bristol-Myers Squibb Pharmaceutical Research Institute (AKA Bristol-Myers Squibb Company), where he was responsible for identifying, evaluating and negotiating numerous pre-clinical lead compound collaborations and platform technology alliances. Before his 11-year career at Bristol-Myers Squibb, Dr. McAndrew served seven years in conducting basic research at the Roche Institute of Molecular Biology at Hoffmann LaRoche. He has B.S. from State University College at Oswego, New York and Ph.D. in Molecular and Cellular Biology from Ohio University and MS is Molecular Genetics from the State University of New York.

Mr. Lawrence A. Kenyon, also known as Larry, CPA, has been Chief Financial Officer and Secretary of Oncobiologics, Inc. since September 15, 2015 and also serves as its Principal Accounting Officer. Mr. Kenyon served as the Chief Financial Officer of Arno Therapeutics, Inc. from February 27, 2014 to September 15, 2015 and as its Chief Operating Officer from July 18, 2014 to September 15, 2015 and also served as its Principal Accounting Officer. Mr. Kenyon served as the Chief Executive Officer of Tamir Biotechnology, Inc. (formerly known as Alfacell Corp.) until March 31, 2013 and served as its Chief Financial Officer since December 23, 2011 and served as its President and Corporate Secretary. Mr. Kenyon served as an Interim Chief Executive Officer of Tamir Biotechnology, Inc. since December 23, 2011 and served as its acting president from December 2008 to January 2009. Mr. Kenyon served as the Chief Financial Officer and Executive Vice President of Par Pharmaceutical Companies Inc. from March 9, 2009 to June 30, 2010. Mr. Kenyon has strong financial, investor relations and leadership skills. Mr. Kenyon served as Acting President, Acting Chief Financial Officer and Acting Corporate Secretary of Alfacell Corp. from December 2008 to January 31, 2009. Mr. Kenyon was responsible for all financial aspects of Alfacell. Mr. Kenyon served as an Executive Vice President of Finance at Par Pharmaceutical Companies Inc. and Par Pharmaceutical, Inc. since December 15, 2008. He served as the Chief Financial Officer and Company Secretary of Alfacell Corp. from January 17, 2007 to December 2008. He served as Chief Operating Officer of Alfacell Corp. from November 2007 to December 2008 and its Principal Accounting Officer and President until December 2008. He served as Executive Vice President of Alfacell Corp. since January 17, 2007. Mr. Kenyon served as Chief Financial Officer of NeoPharm Inc. from September 2000 to August 31, 2006 and also served as its Principal Accounting Officer, Corporate Secretary and Executive Vice President until August 31, 2006. Mr. Kenyon began his career with Arthur Andersen & Co. From October 1999 to September 2000, he served as Senior Vice President of the Gabelli Mathers Fund. From 1988 to 2000, Mr. Kenyon held a variety of senior executive positions with Mathers & Company, Inc. and its affiliated companies most recently as a chief financial officer. He served as a Director of Alfacell Corp., from November 2007 to January 31, 2009. Mr. Kenyon holds a B.B.A. in Accounting from the University of Wisconsin???Whitewater in 1987. He is a Certified Public Accountant in Illinois.

Dr. Kenneth M. Bahrt, M.D., F.A.C.R., has been the Chief Medical Officer of Oncobiologics, Inc. since June 2015. Dr. Bahrt served as the Chief Medical Officer and Senior Vice President at Savient Pharmaceuticals, Inc. since July 1, 2011. Dr. Bahrt led the overall management of Savient's clinical development, drug safety and medical affairs teams. From 2009 to 2011, he served as Therapeutic Area Head for US Medical Affairs (Immunology) at Genentech, a wholly owned subsidiary of F. Hoffmann-LaRoche, Inc. From 2007 to 2009, he served as Global Medical Director of Inflammation and Immunology at F. Hoffmann???La Roche, Inc, a pharmaceutical and diagnostics company. Additionally, from 2004 to 2007, Dr. Bahrt worked in leadership positions of increasing breadth and responsibility at Bristol Meyers Squibb Co., a global biopharmaceutical company, where he was the Executive Director of Global Medical Affairs (Immunology). Prior to that, he worked at Pfizer, a biopharmaceutical company from 2000 to 2004, where he served as Medical Director and Team Leader for rheumatology portfolio products. From 1999 to 2000, he was employed at Daiichi Pharmaceuticals, Inc. as Director of Clinical Development. Prior to joining the pharmaceutical industry, he had a rheumatology practice for 15 years. Dr. Bahrt is a board certified rheumatologist.

Kenneth Bahrt serves as the Chief Medical Officer of Oncobiologics Inc.. Kenneth started at Oncobiologics Inc. in Jun of 2015. Kenneth currently resides in the Greater New York City Area.

Myrna Thomas serves as the Vice President, QA/QC,RA of Oncobiologics Inc.. Myrna currently resides in the Greater Philadelphia Area.